{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:50Z","timestamp":1787026550124,"version":"build-2736575974"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01354","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T09:58:54Z","timestamp":1603274334000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review"],"prefix":"10.3389","volume":"11","author":[{"given":"Nabil E.","family":"Omar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem A.","family":"El-Fass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman I.","family":"Abushouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Elbaghdady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd Elmonem M.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E.","family":"Noreldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Johar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Elazzazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Dermime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.molmed.2015.05.005","article-title":"Checkpoint blockade for cancer therapy : revitalizing a suppressed immune system","volume":"21","author":"Pico de Coa\u00f1a","year":"2015","journal-title":"Trends Mol Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMx100063","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2016.06.026","article-title":"Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab","volume":"99","author":"Tabchi","year":"2016","journal-title":"Lung Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/med.21478","article-title":"Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: what we know, what we do not know, and what we can do to prevent adverse effects","volume":"38","author":"Spallarossa","year":"2018","journal-title":"Med Res Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/23809000.2016.1142827","article-title":"The management of immune-related adverse events associated with immune checkpoint blockade","volume":"1","author":"Fay","year":"2016","journal-title":"Expert Rev Qual Life Cancer Care."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.04.004","article-title":"Immune-related bone marrow failure following anti-PD1 therapy","volume":"80","author":"Michot","year":"2017","journal-title":"Eur J Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2015.10.073","article-title":"Two cases of immune thrombocytopenia associated with pembrolizumab","volume":"54","author":"Le Roy","year":"2016","journal-title":"Eur J Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1159\/000479237","article-title":"A case of immune thrombocytopenia as a rare side effect of an immunotherapy with PD1-blocking agents for metastatic melanoma","volume":"44","author":"Pf\u00f6hler","year":"2017","journal-title":"Transfus Med Hemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7812\/TPP\/17-004","article-title":"Pembrolizumab-Induced pancytopenia: a case report","volume":"21","author":"Atwal","year":"2017","journal-title":"Perm J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMc1509362","article-title":"Immunotherapy-associated hemolytic anemia with pure red-cell aplasia","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/CAD.0000000000000661","article-title":"A case of severe pembrolizumab-induced neutropenia","volume":"29","author":"Barbacki","year":"2018","journal-title":"Anticancer Drugs."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/annonc\/mdx113","article-title":"Pembrolizumab associated hemophagocytic lymphohistiocytosis","volume":"28","author":"Shah","year":"2017","journal-title":"Ann Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1182\/blood.V126.23.4543.4543","article-title":"Evan's syndrome associated with pembrolizumab therapy in metastatic non-small cell lung cancer","volume":"126","author":"Lott","year":"2015","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10637-018-0561-5","article-title":"Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report","volume":"36","author":"Ogawa","year":"2018","journal-title":"Invest New Drugs."},{"key":"B18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ejca.2018.07.318","article-title":"A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica","volume":"103","author":"Robilliard","year":"2018","journal-title":"Eur J Cancer."},{"key":"B19","first-page":"1","article-title":"IGT84: pembrolizumab induced autoimmune hemolytic anemia with possible","author":"Sherbeck","year":"2018","journal-title":"American Association of Blood Banks (AABB) Annual Meeting"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e4283","DOI":"10.1097\/MD.0000000000004283","article-title":"Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: a case report","volume":"95","author":"Inadomi","year":"2016","journal-title":"Medicine."},{"key":"B21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lungcan.2018.02.018","article-title":"Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma","volume":"119","author":"Tokumo","year":"2018","journal-title":"Lung Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrc.2016.02.009","article-title":"Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer","volume":"6","author":"Bagley","year":"2016","journal-title":"Cancer Treat Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000477968","article-title":"Immune thrombocytopenia induced by nivolumab in a metastatic non-small cell lung cancer patient","volume":"40","author":"Karakas","year":"2017","journal-title":"Oncol Res Treat."},{"key":"B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2217\/imt-2017-0100","article-title":"Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab","volume":"10","author":"Jotatsu","year":"2018","journal-title":"Immunotherapy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/annonc\/mdv580","article-title":"Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells","volume":"27","author":"Kanameishi","year":"2016","journal-title":"Ann Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/CAD.0000000000000520","article-title":"Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab","volume":"28","author":"Turgeman","year":"2017","journal-title":"Anticancer Drugs."},{"key":"B27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CMR.0000000000000232","article-title":"Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma","volume":"26","author":"Kong","year":"2016","journal-title":"Melanoma Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000447508","article-title":"Development of hemolytic anemia in a nivolumab-treated patient with refractory metastatic squamous cell skin cancer and chronic lymphatic leukemia","volume":"9","author":"Schwab","year":"2016","journal-title":"Case Rep Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1159\/000452296","article-title":"Autoimmune hemolytic anemia as a complication of nivolumab therapy","volume":"9","author":"Palla","year":"2016","journal-title":"Case Rep Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1078155217726159","article-title":"Nivolumab-induced aplastic anemia: a case report and literature review","volume":"25","author":"Comito","year":"2019","journal-title":"J Oncol Pharm Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/CMR.0000000000000392","article-title":"A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma","volume":"27","author":"Yuki","year":"2017","journal-title":"Melanoma Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1097\/TP.0000000000001861","article-title":"Severe allograft rejection and autoimmune hemolytic anemia after anti-PD1 therapy in a kidney transplanted patient","volume":"101","author":"Deltombe","year":"2017","journal-title":"Transplantation."},{"key":"B33","doi-asserted-by":"publisher","first-page":"mdw537","DOI":"10.1093\/annonc\/mdw537","article-title":"Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression","volume":"28","author":"Takeshita","year":"2016","journal-title":"Ann Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/j.jtho.2018.06.024","article-title":"Nivolumab-induced hemophilia a presenting as gastric ulcer bleeding in a patient with NSCLC","volume":"13","author":"Kato","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/CJI.0000000000000041","article-title":"Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma","volume":"37","author":"du Rusquec","year":"2014","journal-title":"J Immunother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00262-010-0958-2","article-title":"Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)","volume":"60","author":"Di Giacomo","year":"2011","journal-title":"Cancer Immunol Immunother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS ONE."},{"key":"B38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1078155211411001","article-title":"Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma","volume":"18","author":"Ahmad","year":"2012","journal-title":"J Oncol Pharm Pract."},{"key":"B39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/jjco\/hyu222","article-title":"Treatment possibilities of ipilimumab-induced thrombocytopenia\u2013case study and literature review","volume":"45","author":"Kopeck\u00fd","year":"2015","journal-title":"Jpn J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","article-title":"Neutropenia in a patient treated with ipilimumab (anti\u2013CTLA-4 Antibody)","volume":"32","author":"Akhtari","year":"2009","journal-title":"J Immunother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000377650","article-title":"Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report","volume":"38","author":"Wozniak","year":"2015","journal-title":"Oncol Res Treat."},{"key":"B42","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1752-1947-8-240","article-title":"Serious haematological toxicity during and after ipilimumab treatment: a case series","volume":"8","author":"Simeone","year":"2014","journal-title":"J Med Case Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"232470961666183","DOI":"10.1177\/2324709616661835","article-title":"Ipilimumab-induced neutropenia in melanoma","volume":"4","author":"Ban-Hoefen","year":"2016","journal-title":"J Investig Med High Impact Case Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2162-3619-1-3","article-title":"Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma","volume":"1","author":"Wei","year":"2012","journal-title":"Exp Hematol Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1056\/NEJMc1113863","article-title":"Hemophilia A induced by ipilimumab","volume":"366","author":"Delyon","year":"2012","journal-title":"N Engl J Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00262-008-0627-x","article-title":"Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma","volume":"58","author":"Gordon","year":"2009","journal-title":"Cancer Immunol Immunother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/annonc\/mdx701","article-title":"Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors","volume":"29","author":"Michot","year":"2018","journal-title":"Ann Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/annonc\/mdx693","article-title":"A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor","volume":"29","author":"Leroy","year":"2018","journal-title":"Ann Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ddg.13722","article-title":"Lethal thrombocytopenia in a patient treated with avelumab for metastatic Merkel cell carcinoma","volume":"17","author":"Kratzsch","year":"2018","journal-title":"J Dtsch Dermatol Ges."},{"key":"B50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/annonc\/mdx177","article-title":"Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma","volume":"28","author":"Helgadottir","year":"2017","journal-title":"Ann Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40425-017-0214-9","article-title":"Immunotherapy-associated autoimmune hemolytic anemia","volume":"5","author":"Khan","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/CJI.0000000000000194","article-title":"Management of immune-mediated cytopenias in the era of cancer immunotherapy","volume":"41","author":"Sun","year":"2018","journal-title":"J Immunother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2017.05.017","article-title":"Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies","volume":"81","author":"Bernard-Tessier","year":"2017","journal-title":"Eur J Cancer."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40164-018-0098-5","article-title":"Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report","volume":"7","author":"Meyers","year":"2018","journal-title":"Exp Hematol Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"key":"B57","first-page":"1372","article-title":"How to read a case report (or teaching case of the month)","volume":"54","author":"Pierson","year":"2009","journal-title":"Respir Care."},{"key":"B58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","article-title":"Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma","volume":"166","author":"Quirk","year":"2015","journal-title":"Transl Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S0895-4356(00)00188-8","article-title":"What contributions do languages other than English make on the results of meta-analyses?","volume":"53","author":"Moher","year":"2000","journal-title":"J Clin Epidemiol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.01354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T13:41:25Z","timestamp":1603978885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.01354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2020.01354"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01354","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"article-number":"1354"}}